Synchron Secures $200 Million Series D Financing to Advance Stentrode, the World’s First Endovascular Brain-Computer Interface
Synchron
Developer of implantable neural interface products
Double Point Ventures
Venture Capital Firms
Khosla Ventures
Venture Capital Firms
Bezos Expeditions
Venture Capital Firms
T.Rx Capital
Venture Capital Firm
K5 Global
New Media and Financial Services Consulting Firm
ARCH Ventures Partners
Healthcare Investment Firms
Neurotechnology Investors
Investment Institutions
Australian National Reconstruction Fund
--
Qatar Investment Authority
National Wealth Fund
Protocol Labs
--
IQT
--
METIS innovative
--
SynchronAnnounced Completion of NewA $200 million financing round,This RoundFinancing byLed by Double Point Ventures, with participation from ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, METIS,Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQTCo-investment. This round of financing will be used to accelerate its first-generation brain-computer interfaceStentrodethe commercialization process and promote the research and development of cutting-edge next-generation interfaces.
Upon completion of the original financing,Synchronwith total financing reaching $345 million.
Investor Evaluation
"Synchron is building the first truly scalable, minimally invasive brain-computer interface, which holds promise for application in everyday healthcare. By integrating neurovascular access technology, groundbreaking device engineering, and adaptive artificial intelligence, it marks a fundamental step forward in helping paralyzed patients restore digital capabilities."
---Campbell Murray Co-Founder and Managing Partner of Double Point Ventures
"Synchron’s work is expanding the boundaries of what is possible between the human brain and technology, bringing us closer to a future in which brain-computer interfaces are poised to unlock entirely new dimensions in healthcare."
---Bob Langer Executive Chairman of T.Rx Capital
Executive Evaluation
"We have developed the first non-surgical brain-computer interface specifically designed for the daily lives of paralyzed patients. This funding brings us closer to commercializing the Stentrode brain-computer interface platform and accelerates a major breakthrough in the field—the development of a new generation of transcatheter, high-channel, whole-brain interfaces."
---Tom Oxley Synchron CEO and Founder
Synchron’s Brain-Computer Interface Product—Stentrode—is the world’s first endovascular brain-computer interface, designed to translate brain activity into digital commands without the need for open-brain surgery. Stentrode is implanted via a minimally invasive catheter-based procedure, interacting with the brain’s motor cortex through blood vessels to record and wirelessly transmit neural signals, thereby enabling hands-free control of digital devices. To date, 10 paralyzed patients in clinical trials in the United States and Australia have received the Stentrode brain-computer interface implant.
StentrodeVery similar to those used for traditional cerebrovascular stents,StentrodeIt consists of a tiny stent that expands within the blood vessel to secure it in place; 16 micro-sensors are then mounted on it to capture brain activity.
Minimally Invasive Percutaneous Endovascular Intervention—No surgical craniotomy is required. Other therapeutic devices necessitate a craniotomy for implantation, involving the removal of the skull. These devices are inserted into brain tissue, potentially causing damage, and the associated neural signals from this region may gradually diminish. Short Surgical Duration----Takes only 30–40 minutes; High recording capacity—each platinum (Pt) circular electrode can record electrical activity from approximately 10,000 neurons; Can be transmitted via a wireless system in the chest to an external prosthetic limb equipped with a computer; Safety—Implantation via the jugular vein reduces or avoids the risk of stroke.
